MARKET

APGE

APGE

Apogee Therapeutics Inc
NASDAQ
62.24
+0.11
+0.18%
After Hours: 62.03 -0.21 -0.34% 18:51 02/06 EST
OPEN
64.45
PREV CLOSE
62.13
HIGH
64.95
LOW
61.75
VOLUME
1.37M
TURNOVER
--
52 WEEK HIGH
84.56
52 WEEK LOW
26.20
MARKET CAP
4.25B
P/E (TTM)
-14.2670
1D
5D
1M
3M
1Y
5Y
1D
Apogee Therapeutics to Participate in Guggenheim Emerging Outlook Biotech Summit
Reuters · 3d ago
Apogee Therapeutics Chief Medical Officer Carl Dambkowski Reports Disposal of Common Shares
Reuters · 3d ago
Apogee Therapeutics CFO Jane Henderson Reports Sale of Common Shares
Reuters · 3d ago
APOGEE THERAPEUTICS INC <APGE.O>: JEFFERIES CUTS TARGET PRICE TO $95 FROM $98
Reuters · 6d ago
Weekly Report: what happened at APGE last week (0126-0130)?
Weekly Report · 6d ago
13D Filings
Barron‘s · 01/31 00:39
Analysts Are Bullish on These Healthcare Stocks: Concentra Group Holdings Parent, Inc. (CON), Apogee Therapeutics (APGE)
TipRanks · 01/30 18:20
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), GE Healthcare Technologies Inc (GEHC) and Apogee Therapeutics (APGE)
TipRanks · 01/30 18:10
More
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.

Webull offers Apogee Therapeutics Inc stock information, including NASDAQ: APGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APGE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APGE stock methods without spending real money on the virtual paper trading platform.